MiNK Therapeutics falls after over 700% surge in previous session

Mink Therapeutics

14/07/2025 13:23

** Shares of drug developer MiNK Therapeutics INKT.O fall 31% to $44.30 premarket after over 700% rise in previous session

** H.C. Wainwright analyst Emily Bodnar says it is reversing gains from Friday's cancer therapy trial data

** INKT's experimental allogeneic cell therapy, agenT-797, showcased complete remission in one patient with advanced testicular cancer, as published in Oncogene

** Mid-stage data expected in upcoming months and study is enrolling patients, co said

** Up to last close, stock up 820.79% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))